Project Grant F31CA306101
Award Date 1/15/26
Completion Date 7/31/27
Dollars Obligated $99K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to Case Western Reserve University to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The research aims to gain a better understanding of GSC biology and the post-transcriptional regulatory mechanisms that enable them to thrive in both low and normal oxygen conditions, promoting glioblastoma tumor growth....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $451,996 to the University of Texas at Arlington (UTA) to develop high-throughput screening platforms for identifying and validating drugs that can target migrating and treatment-resistant glioblastoma (GBM) cancer cells. The overarching goal is to transform GBM, which is currently a fatal disease, into a more localized condition that can be effectively treated through surgery and/or...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research on a novel signaling axis involving the protein connexin 43 (CX43) and its role in regulating cancer stem cells in glioblastoma, the most common and deadly form of brain cancer. The $161,000 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve...
- This federal Project Grant award of $131,360 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research at the University of New Haven to characterize the long non-coding RNA GIHCG and assess its potential as a therapeutic target for glioblastoma, the most aggressive form of brain cancer. The 4-year project aims to use CRISPR/Cas9 gene editing to...
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $848,286 to the University of South Florida to conduct research on the role of N6-methyladenosine (m6A) RNA modifications in Alzheimer's disease (AD). The key objectives are to: 1) Create a high-resolution map of m6A sites in the brains of older adults, 2) Identify specific m6A alterations associated with AD and its clinical/pathological features, and 3) Elucidate how m6A dysregulation may...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop novel small molecule inhibitors targeting the MBD2 protein for epigenetic therapy of medulloblastoma (MB), a common and aggressive pediatric brain cancer. The $564,045 award supports medicinal chemistry optimization of a lead compound, KCC07, which has shown promise in...
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- This federal Project Grant award of $433,125.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of the RNA binding protein SERBP1 in regulating epigenetic processes and gene expression changes that contribute to glioblastoma development and cell fate decisions. The key objectives are to establish connections...